Better Living Peptides
BLP RESEARCH HUBResearch. Regeneration. Results.

WEIGHT & METABOLIC HEALTHHORMONE & REPRODUCTIVE HEALTHMUSCLE, GROWTH & RECOVERY

Tesamorelin

Studied specifically for reducing deep abdominal fat—the kind that surrounds the internal organs.

Tesamorelin prompts the body to release its own growth hormone, and has been studied specifically for reducing visceral fat—the deep abdominal fat that surrounds internal organs and is strongly linked to insulin resistance and cardiovascular risk. It is FDA-approved for a specific clinical indication (HIV-associated lipodystrophy).

GHRH AnalogVisceral FatGH / IGF-1 AxisMetabolic Health

Why BLP features Tesamorelin

Included because it is FDA-approved (for a specific indication), works through a well-characterized GHRH-receptor mechanism, and has a defined clinical track record. It represents targeted, established metabolic research rather than broad weight-loss marketing.

Mechanism

Binds the receptors on the pituitary gland that trigger the body's own release of growth hormone and IGF-1, its main downstream signal.

Preferentially targets deep abdominal fat stores; in studies it did not reduce fat under the skin, and lean mass was preserved or modestly increased.

WHAT THE RESEARCH MEASURED

Research findings

Findings describe study outcomes, not expected personal results.

Human research findings

  • Reported significant visceral fat reduction (roughly 15–20% over 26 weeks versus placebo in Phase 3 HIV-lipodystrophy trials).
  • Reported lean body mass increase of roughly +1.2 to +1.4 kg over 26 weeks versus placebo in Phase 3 and pooled analyses; a secondary CT analysis showed increased density and area in trunk muscles (e.g., rectus, psoas) among VAT responders.
  • Reported improved lipid profiles and insulin sensitivity, and better waist circumference and body composition.
  • Reported substantial IGF-1 increases at 2 mg daily—on the order of +65–80% (about +80–110 ng/mL) in Phase 3 analyses, higher in a short study of healthy men—while GH release stayed pulsatile and IGF-1 usually stayed within or near the upper physiological range, not rhGH-like.
  • Side effects were mostly mild: injection-site reactions that usually faded after the first week; rare joint pain or mild glucose changes.

Mechanistic & supporting research

  • GHRH-receptor mechanism well characterized.
  • VAT-specific targeting established through the GH/IGF-1 axis.

Regulatory status

Tesamorelin is FDA-approved for a specific clinical indication (HIV-associated lipodystrophy) and is not approved for general weight loss. Material offered here is sold and offered strictly for laboratory and research use.

Related research

RetatrutideSermorelinIpamorelin/CJC-1295Evidence FrameworkResearch Library